

DAFTAR PUSTAKA

- Akslen, L.A., Puntervoll, H., Bachmann, I.M., Straume, O., Vuhahula, E., Kumar, R., Molven, A., 2008. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. *Melanoma Res.* 18, 29–35.
- Balch, C.M., 2009. Microscopic Satellites Around a Primary Melanoma: Another Piece of the Puzzle in Melanoma Staging. *Ann Surg Oncol.* 16, 1092–1094.
- Behjati, S., Tarpey, P.S., 2013. What is next generation sequencing? *Arch Dis Child Educ Pract Ed.* 98, 236–238.
- Bosserhoff, A.K., 2017. Melanoma Development: Molecular Biology, Genetics and Clinical Application. Springer. 1-433.
- Carlino, M.S., Haydu, L.E., Kakavand, H., Menzies, A.M., Hamilton, A.L., Yu, B., *et al.*, 2014. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. *Br. J. Cancer.* 111, 292–299.
- Choi, D.Y., Lee, S.P., Park, S., 2014. Prevalence of *BRAF* and *NRAS* Mutations and a Comparative Analysis in Primary and Metastatic Melanoma of Korean Patients. *Ewha Med J.* 37, 30.
- Cichorek, M., Wachulska, M., Stasiewicz, A., Tymińska, A., 2013. Skin melanocytes: biology and development. *Postepy Dermatol Alergol.* 30, 30–41.
- Cohen, L.M., 1995. Lentigo maligna and lentigo maligna melanoma. *J. Am. Acad. Dermatol.* 33, 923–936; quiz 937–940.
- Colicelli, J., 2004. Human RAS Superfamily Proteins and Related GTPases. *Sci STKE.* 13.
- Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., *et al.*, 2012. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. *J. Clin. Oncol.* 30, 2522–2529.
- Corvino, A., Corvino, F., Catalano, O., Sandomenico, F., Petrillo, A., 2017. The Tail and the String Sign: New Sonographic Features of Subcutaneous Melanoma Metastasis. *J. ultrasmedbio.* 370-374.
- Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., *et al.*, 2005. Distinct Sets of Genetic Alterations in Melanoma. *N Engl J Med.* 353, 2135–2147.

- Dickson, P.V., Gershenwald, J.E., 2011. Staging and prognosis of cutaneous melanoma. *Surg. Oncol. Clin. N. Am.* 20, 1–17.
- Elder, D.E., Massi, D., Willemze, R., Scolyer, R., 2018. WHO Classification of Skin Tumors. International Agency for Research on Cancer.
- Erdei, E., Torres, S.M., 2010. A new understanding in the epidemiology of melanoma. *Expert Rev Anticancer Ther* 10, 1811–1823.
- Evrenos, M.K., Temiz, P., Çam, F.S., Yaman, M., Yoleri, L., Ermertcan, A.T., 2018. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population. *Turk J Med Sci.* 48, 973–979.
- Fernández-Medarde, A., Santos, E., 2011. Ras in Cancer and Developmental Diseases. *Genes Cancer.* 2, 344–358.
- Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., *et al.*, 2016. European Dermatology Forum (EDF), European Association of Dermato-Oncology (EADO), European Organisation for Research and Treatment of Cancer (EORTC), 2016. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. *Eur. J. Cancer.* 63, 201–217.
- Gershenwald, J.E., Scolyer, R.A., Hess, K.R., Sondak, V.K., Long, G.V., Ross, M.I., *et al.*, 2017. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 67, 472–492.
- Hamdani Chairil, Ham Maria Fransisca, Siregar Chairani Siregar., 2012. Patologi Molekuler. Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta. 7-114.
- Henrique, R., Azevedo, R., Bento, M.J., Domingues, J.C., Silva, C., Jerónimo, C., 2000. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. *JAAD.* 43, 991–1000.
- Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., *et al.*, 2017. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. *BMC Cancer.* 17, 536.
- Hobbs, G.A., Der, C.J., Rossman, K.L., 2016. RAS isoforms and mutations in cancer at a glance. *J Cell Sci.* 129, 1287–1292.
- Homsí, J., Kashani-Sabet, M., Messina, J.L., Daud, A., 2005. Cutaneous melanoma: prognostic factors. *Cancer Control.* 12, 223–229.

- Jakob, J.A., Bassett, R.L., Ng, C.S., Curry, J.L., Joseph, R.W., Alvarado, G.C., *et al.*, 2012. NRAS mutation status is an independent prognostic factor in metastatic melanoma. *Cancer. PMC*. 118, 4014–4023.
- Johnson, D.B., Puzanov, I., 2015. Treatment of NRAS-mutant melanoma. *Curr Treat Options Oncol*. 16, 15.
- Jones, A.M., Ferguson, P., Gardner, J., Rooker, S., Sutton, T., Ahn, A., Chatterjee, A., *et al.*, 2016. NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. *Oncotarget*. 7, 41017–41030.
- Kalkhoran, S., Milne, O., Zalaudek, I., Puig, S., Malvehy, J., Kelly, J.W., *et al.*, 2010. Historical, Clinical, and Dermoscopic Characteristics of Thin Nodular Melanoma. *Arch Dermatol*. 146, 311–318.
- Kaufman, H.L., Mehnert, J.M. (Eds.), 2016. Melanoma, Cancer Treatment and Research. Springer International Publishing. 1-413.
- Kementerian Pemberdayaan Perempuan dan perlindungan Anak (KKP dan PA)., 2016. BPS: Profil perempuan Indonesia 20011-2015.
- Kim, S.Y., Yun, S.J., 2016. Cutaneous Melanoma in Asians. *Chonnam Med J*. 52, 185–193.
- Kulski, J., 2016. Next-Generation Sequencing — An Overview of the History, Tools, and "Omic" Applications. pp. 3–60.
- Lee, H.Y., Chay, W.Y., Tang, M.B., Chio, M.T., Tan, S.H., 2012. Melanoma: differences between Asian and Caucasian patients. *Ann. Acad. Med. Singap*. 41, 17–20.
- Lilyquist, J., White, K.A.M., Lee, R.J., Philips, G.K., Hughes, C.R., Torres, S.M., 2017. Quantitative Analysis of Immunohistochemistry in Melanoma Tumors. *Medicine (Baltimore)*. 96.
- Lindberg, M.R., 2017. Diagnostic Pathology: Normal Histology. Elsevier. 42-43.
- Malumbres, M., Pellicer, A., 1998. RAS pathways to cell cycle control and cell transformation. *Front. Biosci*. 3, d887-912.
- Muñoz-Couselo, E., Adelantado, E.Z., Ortiz, C., García, J.S., Perez-Garcia, J., 2017. NRAS-mutant melanoma: current challenges and future prospect. *Onco Targets Ther*. 10, 3941–3947.

- National Comprehensive Cancer Network (NCCN), 2018, *Melanoma (Version 1.2018)*, Retrieved from <https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf>.
- Nam, K.W., Bae, Y.C., Nam, S.B., Kim, J.H., Kim, H.S., Choi, Y.J., 2016. Characteristics and Treatment of Cutaneous Melanoma of the Foot. *Arch Plast Surg*. 43, 59–65.
- Painter, J.T., Clayton, N.P., Herbert, R.A., 2009. Useful Immunohistochemical Markers of Tumor Differentiation: *Toxicol Pathol*. 389(1), 131-141.
- Pasaribu, E., setiaji, K., rinonce, H., azhar, Y., Wahyono, A., pasaribu, E., 2019. Clinical and pathological profile of skin melanoma in Dr. Sardjito Hospital Yogyakarta, Indonesia. *EJSO*. 45, 137.
- Patterson, J.W., 2014. Weedon's Skin Pathology E-Book. Elsevier Health Sciences. 1-783.
- Posch, C., Sanlorenzo, M., Vujic, I., Oses-Prieto, J.A., Cholewa, B.D., Kim, S.T., *et al.*, 2016. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2 α Kinase Levels in NRAS(Q61) Mutant Cells. *JID*. 136, 2041–2048.
- Rapini, R.P., 2012. Practical Dermatopathology E-Book. Elsevier Health Sciences. 285-306.
- Rekhtman, N., Bishop, J.A., 2011. Quick Reference Handbook for Surgical Pathologists. Springer Science & Business Media. 1-138.
- Rinonce, H.T., Aji, R.P.M., Hayati, N., Pudjohartono, M.F., Kameswari, B., Irianiwati, 2019. Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients. *BMC*. 13, 15.
- Sakaizawa, K., Ashida, A., Uchiyama, A., Ito, T., Fujisawa, Y., Ogata, D., *et al.*, 2015. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. *J. Dermatol. Sci*. 80, 33–37.
- Saldanha, G., Potter, L., Daforio, P., Pringle, J.H., 2006. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. *Clin. Cancer Res*. 12, 4499–4505.
- Sheen, Y.-S., Liao, Y.-H., Liao, J.-Y., Lin, M.-H., Hsieh, Y.-C., Jee, S.-H., *et al.*, 2016. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. *JFMA*. 115, 121–127.

- Smoller, B.R., 2006. Histologic criteria for diagnosing primary cutaneous malignant melanoma. *Mod. Pathol.* 19, 34-40.
- The Global Cancer Observatory., 2019. GLOBOCAN fact sheets: melanoma skin.
- Thiagalingam, S., 2015. Systems Biology of Cancer. Cambridge University Press. 94-499.
- Uguen, A., Talagas, M., Costa, S., Samaison, L., Paule, L., Alavi, Z., *et al.*, 2015. NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas. *Diagn Pathol.* 1-10.
- Uhara, H., Ashida, A., Koga, H., Ogawa, E., Uchiyama, A., Uchiyama, R., *et al.*, 2014. NRAS mutations in primary and metastatic melanomas of Japanese patients. *Int J Clin Oncol.* 19, 544-548.
- Usman, H.A., Hernowo, B.S., Tobing, M.D.L., Hindritiani, R., 2018. The Major Role of NF- κ B in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells. *J Pathol Transl Med.* 52, 164-170.
- Zhou, Q.-M., Li, W., Zhang, X., Chen, Y.-B., Chen, X.-C., Guan, Y.-X., *et al.*, 2012. The Mutation Profiles of Common Oncogenes Involved in Melanoma in Southern China. *JID.* 132, 1935-1937.